AU2457100A - Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs - Google Patents

Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs

Info

Publication number
AU2457100A
AU2457100A AU24571/00A AU2457100A AU2457100A AU 2457100 A AU2457100 A AU 2457100A AU 24571/00 A AU24571/00 A AU 24571/00A AU 2457100 A AU2457100 A AU 2457100A AU 2457100 A AU2457100 A AU 2457100A
Authority
AU
Australia
Prior art keywords
oligonucleotidescontaining
motifs
enhancement
bactericidal activity
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24571/00A
Other languages
English (en)
Inventor
Marzia Monica Giuliani
Guido Grandi
Mariagrazia Pizza
Rino Rappuoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Publication of AU2457100A publication Critical patent/AU2457100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU24571/00A 1999-02-26 2000-02-09 Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs Abandoned AU2457100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12179299P 1999-02-26 1999-02-26
US60121792 1999-02-26
PCT/IB2000/000176 WO2000050075A2 (en) 1999-02-26 2000-02-09 Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs

Publications (1)

Publication Number Publication Date
AU2457100A true AU2457100A (en) 2000-09-14

Family

ID=22398817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24571/00A Abandoned AU2457100A (en) 1999-02-26 2000-02-09 Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs

Country Status (11)

Country Link
US (1) US8221761B1 (https=)
EP (1) EP1154790B1 (https=)
JP (2) JP4812942B2 (https=)
AT (1) ATE279943T1 (https=)
AU (1) AU2457100A (https=)
CA (1) CA2371994C (https=)
DE (1) DE60015084T2 (https=)
ES (1) ES2228454T3 (https=)
HK (1) HK1042425B (https=)
PT (1) PT1154790E (https=)
WO (1) WO2000050075A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
NZ515935A (en) * 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
BR0015961A (pt) 1999-11-29 2003-06-10 Chiron Spa Antìgeno de neisseria de 85kda
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
EP1379272B1 (en) * 2001-04-17 2010-01-20 Novartis Vaccines and Diagnostics, Inc. Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes
EP1438323A4 (en) * 2001-10-03 2007-08-01 Novartis Vaccines & Diagnostic ADJUVOUS MENINGOCOCCUS COMPOSITIONS
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
US20050238660A1 (en) * 2001-10-06 2005-10-27 Babiuk Lorne A Cpg formulations and related methods
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) * 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP1047784B2 (en) * 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Neissera meningitidis antigens
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261338A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9820003D0 (en) * 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
GB9826886D0 (en) * 1998-12-07 1999-01-27 Smithkline Beecham Biolog Novel compounds
EP1144643A1 (en) * 1999-01-15 2001-10-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. Neisseria meningitidis antigen
EP1149164A2 (en) * 1999-01-22 2001-10-31 SmithKline Beecham Biologics SA Neisseria meningitidis polypeptides
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
WO2000066741A2 (en) * 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
US7767197B2 (en) * 2000-06-22 2010-08-03 Endo Pharmaceuticals Colorado LLC Delivery vehicle composition and methods for delivering antigens and other drugs
US20040258702A1 (en) * 2000-06-22 2004-12-23 Blonder Joan P. Vaccine delivery
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
MXPA03002643A (es) * 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
EP1379272B1 (en) * 2001-04-17 2010-01-20 Novartis Vaccines and Diagnostics, Inc. Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes
US6541554B2 (en) * 2001-05-17 2003-04-01 Milliken & Company Low-shrink polypropylene fibers
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
EP2263687B1 (en) * 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
BRPI0410423A (pt) * 2003-05-07 2006-06-06 Sanofi Pasteur Inc processo de imunogenicidade melhorada para vacinação meningocócica
US20060182793A1 (en) * 2003-07-22 2006-08-17 Cytos Biotechnology Ag Cpg-packaged liposomes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
GB0401239D0 (en) * 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
KR100721928B1 (ko) * 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
SI1858920T1 (sl) * 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
AR054020A1 (es) * 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
EA015817B1 (ru) * 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
US20090089165A1 (en) * 2007-09-28 2009-04-02 Embarq Holdings Company, Llc System and method for a telephony upgrade credit

Also Published As

Publication number Publication date
WO2000050075A3 (en) 2001-01-11
JP2010174044A (ja) 2010-08-12
HK1042425B (en) 2005-04-01
CA2371994C (en) 2010-09-28
CA2371994A1 (en) 2000-08-31
US8221761B1 (en) 2012-07-17
DE60015084T2 (de) 2006-02-16
PT1154790E (pt) 2005-03-31
EP1154790A2 (en) 2001-11-21
JP4812942B2 (ja) 2011-11-09
JP2002537353A (ja) 2002-11-05
WO2000050075A2 (en) 2000-08-31
ES2228454T3 (es) 2005-04-16
EP1154790B1 (en) 2004-10-20
DE60015084D1 (de) 2004-11-25
ATE279943T1 (de) 2004-11-15
HK1042425A1 (en) 2002-08-16

Similar Documents

Publication Publication Date Title
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2001037863A3 (en) Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen
AU2168902A (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
WO2003094834A3 (en) Mucosal vaccines with chitosan adjuvant and meningococcal antigens
BR0015961A (pt) Antìgeno de neisseria de 85kda
AU2002252638A1 (en) Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase